Expert Consensus on the Use of Isotretinoin in Rejuvenation: A Delphi Study

NCT07296536 | Enrolling By Invitation

• 1 other identifier: Isotretinoin-Rejuvenation
• Study Type: observational
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

This expert consensus project explores the role of low-dose isotretinoin as a rejuvenative and preventive strategy for photoaging and sebaceous-driven skin changes. While isotretinoin is traditionally used for acne, increasing clinical experience suggests that carefully selected micro-dose and low-dose regimens may improve skin texture, pore size, sebaceous activity, and overall skin quality, with potential benefits in skin aging and maintenance rejuvenation programs.

Conditions

Isotretinoin Adverse Reaction; Rejuvenation; Isotretinoin

Keywords

isotretinoin; rejuvenation; consensus; delphi method; Expert pannel

Outcome Measures

Primary Outcomes (1)

• Primary Outcome

  Level of expert consensus on statements regarding the use of isotretinoin for skin rejuvenation, measured as the proportion of panelists reaching a predefined agreement threshold (e.g., ≥70-80%) per statement.

  6-12 weeks

Secondary Outcomes (1)

• Secondary Outcome

  6-12 weeks

Study Arms (1)

Expert Panel

A cohort of dermatology and aesthetic medicine experts participating in a Modified Delphi process to develop consensus recommendations on Isotretinoin in Rejuvenation.

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Target panel: 20-35 experienced dermatologists with practical knowledge of isotretinoin use for rejuvenation or acne. Recruitment: Purposive sampling, stratified to ensure diversity in: Practice setting (academic, private, public) Geographic location Years of experience Baseline data collected: Age, sex, region, practice setting, years of experience, isotretinoin prescribing frequency, research or guideline involvement, declared conflicts of interest. Panel retention strategy: Over-recruit by 10-20% to compensate for attrition; maintain anonymity of responses; clear instructions and timelines for participation.

You may qualify if:

• Board-certified dermatologists or equivalent.
• years clinical experience in dermatology.
• Practical experience prescribing isotretinoin, including low- or micro-dose regimens for rejuvenation or acne.
• Active engagement in clinical dermatology, teaching, research, or guideline development.
• Willingness to participate in all Delphi rounds and provide informed consent.

You may not qualify if:

• Non-dermatology specialists.
• Less than 5 years of clinical experience.
• Lack of relevant isotretinoin experience.
• Significant undisclosed conflict of interest with isotretinoin manufacturers.
• Inability to participate in all Delphi rounds.

Sponsors & Collaborators

• Venus Research Center: lead

Study Sites (1)

Venus Research Center

Cairo, Egypt

Location

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 8, 2025
• First Posted: December 22, 2025
• Study Start: January 25, 2026
• Primary Completion (Estimated): June 1, 2027
• Study Completion (Estimated): September 1, 2027
• Last Updated: December 22, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)